XML 54 R25.htm IDEA: XBRL DOCUMENT v3.25.1
SHARE OPTION PLANS AND ESPP (Tables)
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement, Recognized Amount [Abstract]  
Schedule of stock option plans
A summary of the status of the Company’s option plans as of March 31, 2025 and changes during the period then ended is presented below:
Three months ended March 31, 2025
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year11,315,468 $31.41 
Granted794,616 18.19 
Exercised(348,141)15.07 
Forfeited and canceled(171,758)40.16 
Outstanding as of March 31, 202511,590,185 $30.86 
Exercisable options7,376,472 $35.29 
Schedule of RSUs and PSUs
A summary of the status of the Company’s RSUs and PSUs as of March 31, 2025 and changes during the period then ended is presented below.
Three months ended March 31, 2025
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year12,066,515 $27.19 
Granted4,907,169 19.14 
Vested(2,617,640)23.57 
Forfeited and cancelled(447,281)49.37 
Unvested as of March 31, 2025 (1)13,908,763 24.32 

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of March 31, 2025, in accordance with ASC 718 "Compensation — Stock Compensation" as follows:
 March 31, 2025
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
704,493 $16.30 $11,483 
1,154,720 18.19 21,004 
21,653 19.44 421 
901,284 48.16 43,406 
92,241 76.97 7,100 
2,874,391 $83,414 
Schedule of fair value assumptions used for All equity based awards estimated using black-scholes option pricing model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions: 
Three months ended March 31,Year ended December 31,
2024
20252024
UnauditedAudited
Stock Option Plans
Expected term (years)5.795.73
5.50-5.73
Expected volatility75 %
71%-72%
71%-73%
Risk-free interest rate4.01 %
3.88%-4.28%
3.88%-4.43%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility89 %90 %
73%-90%
Risk-free interest rate4.16 %5.13 %
5.13%-5.23%
Dividend yield0.00 %0.00 %0.00 %
Schedule of non-cash share-based compensation expense related to company's equity-based awards
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2025 and 2024, and the year ended December 31, 2024 was:
Three months ended March 31,Year ended December 31,
2024
20252024
UnauditedAudited
Cost of revenues$1,102 $1,747 $6,873 
Research, development and clinical studies6,201 8,610 32,716 
Sales and marketing8,517 11,048 43,097 
General and administrative13,732 12,679 77,349 
Total share-based compensation expense$29,552 $34,084 $160,035